⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
OCGN News
Ocugen, Inc. Common Stock
Ocugen to Host Conference Call on Tuesday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2026 Financial Results
globenewswire.com
OCGN
Ocugen to Present at April 2026 Investor and Industry Conferences
globenewswire.com
OCGN
Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells
prnewswire.com
VRTX
OCGN
LGVN
LCTX
Centri Announces Panel Topics and Featured Programming for Second Annual Capital Conference at Nasdaq on April 14
accessnewswire.com
NDAQ
DFIN
PTGX
STRL
TNDM
AXSM
CSTL
CYTK
GILD
INSM
KODK
NBIX
OCGN
REGN
SRPT
VRTX
XBIT
AMZN
GOOGL
MSFT
NVDA
IBM
ORGN
BWEN
CCJ
EXC
NEE
SO
UTL
XOM
BALY
OXY
PBF
CHRD
AX
BAC
MAXN
PHIO
KZR
SMX
DUOT
COIN
EHTH
Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease
globenewswire.com
OCGN
Form 8-K
sec.gov
OCGN
Form 8-K
sec.gov
OCGN
Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
globenewswire.com
OCGN
Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy
globenewswire.com
OCGN
Form 8-K
sec.gov
OCGN